More than half of patients with advanced non-small cell lung cancer who took lorlatinib were still alive with no disease progression five years later, a significant improvement over the 8% observed with the standard drug.
These results mark the longest progression-free survival outcomes ever recorded in non-small cell lung cancer patients, presenting a major breakthrough in the treatment of this prevalent form of cancer.
The trial compared lorlatinib and crizotinib in ALK-positive non-small cell lung cancer patients, highlighting the effectiveness of lorlatinib as a targeted treatment that inhibits tumour cell growth.
[
Collection
]
[
|
...
]